Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Hiroki
Mokuda, Sho
Ishitoku, Michinori
Watanabe, Hirofumi
Sugimoto, Tomohiro
Yoshida, Yusuke
Masumoto, Junya
Hirata, Shintaro
- License Information
-
More Information
Article History
Received: 9 February 2026
Accepted: 18 July 2026
First Online: 4 August 2026
Declarations
Ethics approval and consent to participate: This study was approved by the Clinical Ethics Committees of Hiroshima University Hospital, Dohgo Spa Hospital, and the Ehime University Proteo-Science Center and Graduate School of Medicine (approval number: E2016-668-05; approval date: June 18, 2024). Serum and synovial tissues were obtained after the study participants provided informed consent.
Consent for publication: Not applicable.
Competing interests: SH has received speaker’s fees, consultancy fees, or research grants from AbbVie, Asahi-Kasei Pharma, Astellas, AstraZeneca, Ayumi, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, Glaxo SmithKline, Janssen, Nihon-Shinyaku, Novartis, Otsuka Pharmaceutical, Pfizer, Taisho, Tanabe-Mitsubishi, UCB. The other authors declare no conflicts of interest.
